Founders Capital Management (Connecticut)’s Moderna MRNA Stock Holding History

Founders Capital Management (Connecticut)’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$210K	Buy	+3,000	New	+$155K	0.03%	78
2024 Q4	–	Sell	-3,000	Closed	-$200K	–	75
2024 Q3	$200K	Hold	3,000	–	–	0.03%	77
2024 Q2	$356K	Sell	3,000 -20	-0.7%	-$2.53K	0.06%	67
2024 Q1	$322K	Hold	3,020	–	–	0.06%	71
2023 Q4	$300K	Hold	3,020	–	–	0.06%	71
2023 Q3	$312K	Hold	3,020	–	–	0.07%	66
2023 Q2	$367K	Hold	3,020	–	–	0.08%	61
2023 Q1	$464K	Hold	3,020	–	–	0.12%	55
2022 Q4	$542K	Buy	+3,020	New	+$494K	0.15%	53

Other funds holding MRNA

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Founders Capital Management (Connecticut)'s MRNA Position: Q2 2026 in Review

Founders Capital Management (Connecticut) opened a new position in Moderna (MRNA) in Q2 2026: 3,000 shares worth $210K. The stake represents 0.03% of the portfolio and ranks #78 among its holdings. This is a return to the name: Founders Capital Management (Connecticut) previously reported a position in MRNA as recently as Q3 2024.

Founders Capital Management (Connecticut) first reported a position in MRNA in Q4 2022 and has held it in 9 quarters since. The position peaked at $542K in Q4 2022. 184 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Founders Capital Management (Connecticut) held 3,000 shares of Moderna worth $210K as of Q2 2026.
Moderna was a new Founders Capital Management (Connecticut) position in Q2 2026.
Moderna made up 0.03% of Founders Capital Management (Connecticut)'s portfolio in Q2 2026, its #78 holding.
Founders Capital Management (Connecticut) first reported a position in Moderna in Q4 2022 and has held it in 9 quarters since.
Founders Capital Management (Connecticut)'s Moderna position peaked at $542K in Q4 2022.
184 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Founders Capital Management (Connecticut)'s 13F filing for Q2 2026, filed 20 Jul 2026.